Merck Reports Phase 2 Data for Cemiplimab in Biliary tract cancer

Merck today announced Phase 2 results for Cemiplimab in patients with Biliary tract cancer. The study demonstrated that Cemiplimab demonstrates superior efficacy vs standard of care compared to standard of care or placebo. These results provide important insights into the treatment of Biliary tract cancer and support the continued development of Cemiplimab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Cemiplimab was consistent with previous observations, with no new safety signals identified.